Nuvalent Inc (NUVL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 26/100 (MEDIUM), 74.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
- Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
- GSK Buys Nuvalent To Deepen Oncology Focus And Future Lung Cancer Revenue
- GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
- GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
- GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...
- GSK Q2 Earnings Call Highlights
- Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Nuvalent Inc.
Full NUVL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.